-
Endpoints News2 weeks ago
More changes ahead for Takeda with new CEO set to take reins
Takeda’s multi-year restructuring will continue under incoming CEO Julie Kim. The company announced Wednesday that the board has approved “next steps” in its transformation that will...
-
Endpoints News2 weeks ago
How Seaport is hedging against failure in Phase 2b depression study
Seaport Therapeutics is building a fail-safe into its Phase 2b depression trial. The biotech is testing its drug, called SPT-300, in patients with major depressive disorder....
-
Endpoints News2 weeks ago
FDA approves Corcept’s Lifyorli for ovarian cancer months early
The FDA approved Corcept Therapeutics’ Lifyorli in combination with nab-paclitaxel for the treatment of three different kinds of cancer in patients who have received up to...
-
Endpoints News2 weeks ago
After tumultuous year, Sarepta plots rebound with early data on RNA therapies
Sarepta Therapeutics reported promise in initial findings from clinical studies of two RNA muscle disease treatments, as the company maps out a future beyond its controversial...
-
Endpoints News2 weeks ago
Beam looks to accelerated approval for AATD base editing after promising update
Beam Therapeutics has provided a much-awaited update on its therapy that uses a form of CRISPR called base editing to precisely fix a single genetic typo...
-
Endpoints News2 weeks ago
Microneedle vaccine patch company raises $50M for pivot to GLP-1 delivery
Fourteen years ago, a group of Harvard Business School students launched a startup called Vaxess Technologies with a goal to disrupt the vaccine industry by replacing...
-
Endpoints News2 weeks ago
Maze meets own expectations in Phase 2 kidney disease trial in the same arena as Vertex
Maze Therapeutics unveiled positive mid-stage data for its genetic kidney disease drug that could spell major competition for Vertex Pharmaceuticals’ program that has the same target....
-
Endpoints News2 weeks ago
Merck to buy Terns for $6.7B, taking a leukemia drug that could challenge Novartis’ Scemblix
Merck is looking to further solidify its oncology pipeline via a $6.7 billion cash acquisition of Terns Pharmaceuticals and its investigational treatment for chronic myeloid leukemia....
-
Endpoints News2 weeks ago
Gilgamesh’s psychedelics pipeline gets $60M backing after AbbVie deal
Investors have pumped $60 million into Gilgamesh Pharma to test a handful of psychedelics and other experimental neuroscience medicines that the biotech hasn’t yet promised to...
-
Endpoints News2 weeks ago
Ocugen heads to Phase 3 with gene therapy for geographic atrophy
Ocugen said it will take its gene therapy for a form of vision loss into a Phase 3 trial, after reporting mixed results on Tuesday from...
Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay Off
